1
|
Morozova A, Ushakova V, Pavlova O, Bairamova S, Andryshenko N, Ochneva A, Abramova O, Zorkina Y, Spektor VA, Gadisov T, Ukhov A, Zubkov E, Solovieva K, Alexeeva P, Khobta E, Nebogina K, Kozlov A, Klimenko T, Gurina O, Shport S, Kostuyk G, Chekhonin V, Pavlov K. BDNF, DRD4, and HTR2A Gene Allele Frequency Distribution and Association with Mental Illnesses in the European Part of Russia. Genes (Basel) 2024; 15:240. [PMID: 38397229 PMCID: PMC10887670 DOI: 10.3390/genes15020240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 01/31/2024] [Accepted: 02/06/2024] [Indexed: 02/25/2024] Open
Abstract
The prevalence of mental disorders and how they are diagnosed represent some of the major problems in psychiatry. Modern genetic tools offer the potential to reduce the complications concerning diagnosis. However, the vast genetic diversity in the world population requires a closer investigation of any selected populations. In the current research, four polymorphisms, namely rs6265 in BDNF, rs10835210 in BDNF, rs6313 in HTR2A, and rs1800955 in DRD4, were analyzed in a case-control study of 2393 individuals (1639 patients with mental disorders (F20-F29, F30-F48) and 754 controls) from the European part of Russia using the TaqMan SNP genotyping method. Significant associations between rs6265 BDNF and rs1800955 DRD4 and mental impairments were detected when comparing the general group of patients with mental disorders (without separation into diagnoses) to the control group. Associations of rs6265 in BDNF, rs1800955 in DRD4, and rs6313 in HTR2A with schizophrenia in patients from the schizophrenia group separately compared to the control group were also found. The obtained results can extend the concept of a genetic basis for mental disorders in the Russian population and provide a basis for the future improvement in psychiatric diagnostics.
Collapse
Affiliation(s)
- Anna Morozova
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Valeriya Ushakova
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
- Department of Neurobiology, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia
| | - Olga Pavlova
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Sakeena Bairamova
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Nika Andryshenko
- Department of Biology, MSU-BIT Shenzhen University, Shenzhen 518172, China;
| | - Aleksandra Ochneva
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Olga Abramova
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Yana Zorkina
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Valery A. Spektor
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Timur Gadisov
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Andrey Ukhov
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Eugene Zubkov
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Kristina Solovieva
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Polina Alexeeva
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Elena Khobta
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Kira Nebogina
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Alexander Kozlov
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Tatyana Klimenko
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Olga Gurina
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - Svetlana Shport
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
| | - George Kostuyk
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| | - Vladimir Chekhonin
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Department of Medical Nanobiotechnologies, Pirogov Russian National Research Medical University, 117997 Moscow, Russia
| | - Konstantin Pavlov
- V. Serbsky National Medical Research Centre of Psychiatry and Narcology, Kropotkinsky per. 23, 119034 Moscow, Russia; (V.U.); (O.P.); (S.B.); (A.O.); (O.A.); (Y.Z.); (T.G.); (A.U.); (E.Z.); (O.G.); (K.P.)
- Mental-Health Clinic No. 1 Named after N.A. Alekseev, Zagorodnoe Highway 2, 115191 Moscow, Russia
| |
Collapse
|
2
|
Wang H, Farhan M, Xu J, Lazarovici P, Zheng W. The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget 2017; 8:53791-53803. [PMID: 28881851 PMCID: PMC5581150 DOI: 10.18632/oncotarget.17339] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Accepted: 04/12/2017] [Indexed: 02/07/2023] Open
Abstract
Schizophrenia is one of the most devastating heterogeneous psychiatric disorders. The dopamine hypothesis is the longest standing pathoetiologic theory of schizophrenia based on neurochemical evidences of elevated brain striatal dopamine synthesis capacity and increased dopamine release in response to stress. Dopamine and cyclic AMP-regulated phosphoprotein of relative molecular mass 32,000 (DARPP-32) is a cytosolic protein highly enriched in the medium spiny neurons of the neostriatum, considered as the most important integrator between the cortical input and the basal ganglia, and associated with motor control. Accumulating evidences has indicated the involvement of DARPP-32 in the development of schizophrenia; i. DARPP-32 phosphorylation is regulated by several neurotransmitters, including dopamine and glutamate, neurotransmitters implicated in schizophrenia pathogenesis; ii. decrease of both total and phosphorylated DARPP-32 in the prefrontal cortex are observed in schizophrenic animal models; iii. postmortem brain studies indicated decreased expression of DARPP-32 protein in the superior temporal gyrus and dorsolateral prefrontal cortex in patients with schizophrenia; iv. DARPP-32 phosphorylation is increased upon therapy with antipsychotic drugs, such as haloperidol and risperidone which improve behavioral performance in experimental animal models and patients; v. Genetic analysis of the gene coding for DARPP-32 propose an association with schizophrenia. Cumulatively, these findings implicate DARPP-32 protein in schizophrenia and propose it as a potential therapeutic target. Here, we summarize the possible roles of DARPP-32 during the development of schizophrenia and make some recommendations for future research. We propose that DARPP-32 and its interacting proteins may serve as potential therapeutic targets in the treatment of schizophrenia.
Collapse
Affiliation(s)
- Haitao Wang
- Faculty of Health Sciences, University of Macau, Taipa, Macau, China.,School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Mohd Farhan
- Faculty of Health Sciences, University of Macau, Taipa, Macau, China
| | - Jiangping Xu
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Philip Lazarovici
- School of Pharmacy Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Wenhua Zheng
- Faculty of Health Sciences, University of Macau, Taipa, Macau, China
| |
Collapse
|
3
|
Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies. Cell Mol Neurobiol 2015; 36:1-10. [PMID: 26134309 DOI: 10.1007/s10571-015-0229-z] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 06/18/2015] [Indexed: 01/01/2023]
Abstract
According to evidences from previous family and association studies, it has been claimed that genetic factors are involved in the neuropathogenesis of Schizophrenia disorder. Whether the Val66Met variant of brain-derived neurotrophic factor (BDNF) gene plays any roles in the pathogenesis of this syndrome or could be a potential biomarker for prognosis of this disorder has been a long-standing controversial issue. We performed a meta-analysis restricted to case-control studies and searched Pubmed, PsychInfo, and Google scholar using keywords including 'association,' 'Val66Met,' 'BDNF,' and 'schizophrenia' published up to May 1, 2015. A total of 39 studies for schizophrenia were combined by fixed- and random-effects models. The pooled results from the schizophrenia sample indicated no significant evidence for the association of Val/Val and Val/Met genotypes of BDNF gene with schizophrenia, but it was observed that there is an association between Met/Met polymorphism and schizophrenia in Asian, European, and Chinese populations, this means that the risk of schizophrenia in Asian, European, and Chinese populations with Met/Met genotype is, respectively, 9, 26, and 9%. There was a significant association between BDNF Val66Met polymorphism and schizophrenia in our meta-analysis study. We cannot rule out the possibility that other polymorphisms in the BDNF gene are involved in the pathophysiology of schizophrenia. In addition, more studies should be conducted on the polymorphisms in other genes to elucidate their possible roles in schizophrenia.
Collapse
|